An expert perspective pertaining to treatment advances in early-stage non-small cell lung cancer and how to best apply data from ASCO 2023 into daily practice.
EP. 4: Perioperative Treatment in Early-Stage NSCLC: AEGEAN Study
June 29th 2023David Harpole, MD, discusses study design, results and clinical implications of the AEGEAN study of perioperative immunotherapy (neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab in the treatment of early-stage NSCLC
EP. 12: Treatment for Patients Unsuitable for or Refractory to Consolidation Durvalumab
August 3rd 2023Tina Cascone, MD, Ben Levy, MD, and Sandip Patel, MD, offer insights into the treatment approach in patients with unresectable early-stage NSCLC who are unsuitable for consolidation durvalumab or who progress on consolidation durvalumab.